Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.
about
Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implicationsAnti-PEG immunity: emergence, characteristics, and unaddressed questions.Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapyZwitterionic gel encapsulation promotes protein stability, enhances pharmacokinetics, and reduces immunogenicity.A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development PropertiesPre-existing Antibody: Biotherapeutic Modality-Based Review.Extracorporeal delivery of a therapeutic enzyme.Urate-lowering therapy: current options and future prospects for elderly patients with gout.Advances in pharmacotherapy for the treatment of gout.Enzymes approved for human therapy: indications, mechanisms and adverse effects.Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares.The safety of treatment options available for gout.Recent advances in understanding and managing goutFrequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout.A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol.PEG-ing down (and preventing?) the cause of pegloticase failureOutcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation.Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations.Lesinurad for the treatment of hyperuricaemia in people with gout.Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease.Sensitive and Quantitative Detection of Anti-Poly(ethylene glycol) (PEG) Antibodies by Methoxy-PEG-Coated Surface Plasmon Resonance Sensors.Recent pharmacological advances in the management of gout.Physician Awareness of Immune Responses to Polyethylene Glycol-Drug Conjugates.Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer.Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.Impact of pegloticase on patient outcomes in refractory gout: current perspectives
P2860
Q26738948-1E055860-2E5D-4FC0-9698-0B85D3ADE49BQ26825556-B6AB4DCB-0CFB-4AB1-B8F2-8472EFD4FDB8Q27000048-6726084B-1B18-40C8-83CF-86B188BAFA25Q36120371-42935454-5BDA-4AE1-87BE-04592BF0099BQ36230423-7CA8B34A-AA40-4C6A-AEBF-15200EFC00E1Q36653888-A90CBE59-F588-4D99-B00D-8BDD811120C2Q37141213-C0568C54-4938-4D00-98F9-8F0F033B29DFQ38254304-3F0DF75E-FB78-4E4C-984F-0170360478E6Q38303416-6A09836D-DC5A-48E2-8911-0003B65AF21BQ38342838-7C241DD3-00DA-47ED-BE2A-81AD240C6B31Q38704139-5508A4E9-59F0-4C9F-BBCB-96B67D292ED8Q39092018-7C0FF4E3-7E0E-49A3-A477-169DADEE1ABBQ39207801-CEDCD8EA-869A-42F5-861E-E9E133DEFAA3Q40089636-0DA593C1-EDD6-4579-AC4F-3FB97C4FF5A1Q41196820-009C8047-D10C-4092-BCA8-F3E31860C9F5Q42699501-6F7F5B88-395F-4024-A7E1-81CFE8CA767BQ45873829-6C9A933E-6AF6-41D2-85B5-AE8647F9384DQ47102857-ADC2B147-2771-42B5-A74D-F26FCFF06135Q47104100-48689E2E-C367-4B3B-AF54-2A5832DE2077Q47657420-7A17101D-BFC9-442B-A00F-9A5ED4DAD786Q47690427-98BF4329-0837-4BBE-ABB6-7C091AAE9452Q47902077-3C5AC3B9-61D7-4702-9C43-3375100B81E4Q47919692-A61B5BD5-4780-4A23-AAE3-181721F75322Q49565303-F48EC487-F26D-4219-8C07-B3AB7C55CC09Q50285020-EFE0D811-F573-4410-A40E-5430275446B9Q51602149-E7E405C2-E4E1-4724-BC81-533AA01D9731Q58698860-4FA0C83C-BAB2-45D3-8FAA-20772FA9BC37
P2860
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Pegloticase immunogenicity: th ...... d for refractory chronic gout.
@en
type
label
Pegloticase immunogenicity: th ...... d for refractory chronic gout.
@en
prefLabel
Pegloticase immunogenicity: th ...... d for refractory chronic gout.
@en
P2093
P2860
P356
P1476
Pegloticase immunogenicity: th ...... d for refractory chronic gout.
@en
P2093
Arthur Kavanaugh
David Wright
John S Sundy
Leonard H Calabrese
Marsha Wolfson
Michael A Becker
Peter E Lipsky
P2860
P2888
P356
10.1186/AR4497
P577
2014-03-04T00:00:00Z